x

Kyverna Therapeutics, Inc. (Nasdaq:KYTX)

Health Care/Life Sciences • Biotechnology
CIK 1994702
Company

KYVERNA is pioneering a new class of treatments and potential cures for serious autoimmune diseases. The company's therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of inflammatory diseases.

Address
5980 Horton Street
Suite 550
Emeryville, California 94608
Employees
None
Stock Info
Close
$29.49
Day Range
28.37 - 30.22
52 Week Range
26.04 - 35.06
Average volume
602.62K
Short Interest
625.97K (02/29/24)
% of Float Shorted
3.72%
Market Cap
$1.24B
Revenue
$7.03M
Net Income
-$28.89M
2020 Sales Growth
N/A
Rev. per Employee
N/A
P/E Ratio
N/A
EPS
N/A
Yield
N/A
Dividend
N/A
Ex-Dividend Date
N/A
Key Executives
Board Of Directors
Chairman
Ian T Clark
Chief Executive Officer & Director
Peter K Maag PhD
Independent Director
Brian L Kotzin MD
Independent Director
Steve Liapis PhD
Independent Director
Beth C Seidenberg MD
Independent Director
Daniel K Spiegelman MBA
SEC filings
DateFormEvent
26 Nov, 2024 8-K
26 Nov, 2024 S-8
13 Nov, 2024 10-Q
13 Nov, 2024 8-K
12 Nov, 2024 SC 13G
24 Oct, 2024 4
24 Oct, 2024 3
21 Oct, 2024 8-K
10 Oct, 2024 SC 13G
18 Sep, 2024 3
18 Sep, 2024 3
18 Sep, 2024 4
18 Sep, 2024 4
16 Sep, 2024 8-K
12 Aug, 2024 10-Q
12 Aug, 2024 8-K
15 Jul, 2024 8-K
11 Jul, 2024 UPLOAD
14 Jun, 2024 8-K
10 Jun, 2024 4
29 May, 2024 4
14 May, 2024 8-K
14 May, 2024 10-Q
3 May, 2024 SC 13D
26 Mar, 2024 10-K
26 Mar, 2024 8-K
22 Feb, 2024 SC 13G
20 Feb, 2024 SC 13G
14 Feb, 2024 4
14 Feb, 2024 4
14 Feb, 2024 SC 13G
14 Feb, 2024 4
14 Feb, 2024 4
14 Feb, 2024 4
13 Feb, 2024 4
13 Feb, 2024 SEC STAFF
12 Feb, 2024 8-K
12 Feb, 2024 4
8 Feb, 2024 424B4 IPO completed
8 Feb, 2024 S-8
8 Feb, 2024 3
8 Feb, 2024 CERT
8 Feb, 2024 3
7 Feb, 2024 3
7 Feb, 2024 3
7 Feb, 2024 3
7 Feb, 2024 EFFECT
7 Feb, 2024 3
7 Feb, 2024 3
7 Feb, 2024 3
7 Feb, 2024 3
7 Feb, 2024 3
7 Feb, 2024 3
7 Feb, 2024 3
7 Feb, 2024 3
7 Feb, 2024 3
7 Feb, 2024 3
7 Feb, 2024 3
7 Feb, 2024 3
6 Feb, 2024 S-1/A
5 Feb, 2024 8-A12B
5 Feb, 2024 CORRESP
5 Feb, 2024 CORRESP
1 Feb, 2024 S-1/A
25 Jan, 2024 CORRESP
16 Jan, 2024 CORRESP
16 Jan, 2024 S-1
10 Jan, 2024 UPLOAD
8 Jan, 2024 DRS/A
5 Jan, 2024 DRSLTR
28 Dec, 2023 UPLOAD
15 Dec, 2023 SEC STAFF
13 Dec, 2023 DRSLTR
13 Dec, 2023 DRS/A
21 Nov, 2023 UPLOAD
9 Nov, 2023 DRSLTR
9 Nov, 2023 DRS/A
7 Nov, 2023 D
1 Nov, 2023 UPLOAD
5 Oct, 2023 DRS
Last update:2024-03-12 12:02:57.717572
Kyverna Therapeutics, Inc. by TradingView

Sign Up to Subscribe